May 13, 2020

Mastitis Is Not Just a Somatic Cell Count Issue Anymore

E. coli mastitis is known for its quick onset and severe clinical signs

Escherichia coli is different from the mastitis cases we used to see. It’s not simply a somatic cell count issue — it’s a cow health issue. 

“Since I graduated from veterinary school almost 30 years ago, there have been big shifts in the types of mastitis found on farms,” stated Stephen Foulke, DVM, DABVP, Boehringer Ingelheim. “We used to mostly deal with contagious mastitis cases, which we’ve done a good job of managing. Now the mastitis we’re seeing more often are environmental cases, including Gram-negatives like E. coli.”

As environmental pressures such as herd size, stocking density and milk production continue to increase, we’re going to continue to be challenged with Gram-negative mastitis. “When cows come down with E. coli, they can get knocked back hard,” Dr. Foulke said. “They become sick enough that their milk production shuts down, and it can even be fatal. Animals that do recover never really make it back to the peak production they once were at.” 

Preventing E. coli on a dairy operation is a twofold process: 

  1. Address the cow’s environment 

    E. coli and other types of Gram-negative mastitis strains are found virtually anywhere cows are housed, such as in bedding, the milking parlor and manure,” pointed out Dr. Foulke. “We have to keep their environment as clean, dry and comfortable as we can to prevent teat ends from getting exposed to manure.” This includes frequent scraping of alleys and holding pens, as well as keeping stalls, or wherever cows lie down, well-bedded and maintained. 

    “We also need to continue to follow good milking procedures,” advised Dr. Foulke. “That means making sure milking equipment functions properly, and teats are clean and dry before attaching milking equipment. You’ll want to use an effective teat dip immediately after milking and maintain good udder hygiene between milkings.”

  2. Build up the cow’s immunity 
    If faced with E. coli, cows need to have a robust immune response to fight off the infection. Building immunity involves a strong nutrition program that includes trace minerals and plenty of water, as well as vaccination. Vaccination is critical in reducing the severity and incidence of E. coli.1 “Most E. coli infections are going to happen right around freshening, due to increased stress, so I recommend getting ahead of the problem by vaccinating all cows at dry off, then giving a booster vaccine four weeks later,” added Dr. Foulke. “The vaccine you choose should have a short meat withdrawal and provide protection against E. coli, endotoxemia caused by E. coli and Salmonella Typhimurium.” 

If you think you’ve got an animal experiencing a case of E. coli, intramammary antibiotic treatment may not be necessary. “We know from research that not all mastitis cases have to be treated,” Dr. Foulke noted. “In some cases, the cow will cure herself.” That’s why, for mild or moderate mastitis, he recommends producers take a milk sample, culture it and wait for results before treating. 

“Gram-negative mastitis grows very fast, so you can culture and know by the next day what kind of bacteria you have,” said Dr. Foulke. “For those infections that need treatment, such as Gram-positive organisms, knowing the bacteria involved can help you select antibiotics that will be most effective.” However, if cows are visibly sick, start treating immediately with fluids, anti-inflammatories and injectable antibiotics, then adjust treatment as needed based on the culture result.

“Dealing with E. coli starts with your veterinarian,” Dr. Foulke concluded. “He or she can help you create a management and prevention protocol best suited for your operation.”



¹ Animal Health Diagnostic Center. Environmental mastitis. Cornell University, College of Veterinary Medicine. Available at: Accessed Aug. 8, 2019. 



About Boehringer Ingelheim Animal Health USA Inc.  

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. We have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and we aim to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.

Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit, or

About Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.


©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved.